Key takeaways
- Retatrutide is not an approved medicine. As of 2 November 2026 we found no approval from any regulator.
- Reko does not sell it, does not suggest doses and links to no seller.
- Reko only records what a person enters about their own use.
- Reko is not medical advice. Talk to a doctor.
What retatrutide is
Retatrutide is an experimental compound that has been studied in clinical trials. It is not approved by the FDA, the EMA or any other regulator that Reko lists.
Status of trials: Phase 3 trials have finished in obesity, in obesity with type 2 diabetes, in obesity with cardiovascular disease and in knee osteoarthritis, and others are still running, including a comparison with tirzepatide and a cardiovascular and kidney outcomes trial (ClinicalTrials.gov, checked 2 November 2026). Peer-reviewed results so far are two phase 2 trials published in 2023 (obesity, type 2 diabetes) and a phase 3 sleep apnea paper published in the New England Journal of Medicine on 21 October 2026. Results Lilly has announced by press release are not peer-reviewed and are not summarised here.
If you take part in a trial, follow your study team. They decide the amount and the schedule.
What Reko does not do
- It does not sell retatrutide or any other medicine.
- It does not suggest a dose, a schedule or a source.
- It does not link to any seller.
- It does not say retatrutide is safe or that it works.
What Reko records
Reko is a diary. If you use something that has no approval, a record at least keeps the facts straight.
- The amount and time you enter, and the injection site on a body map.
- Side effects, written beside the dose they followed.
- Weight over time, and lab results you scan and check.
- An estimated level curve, only where a compound has published half-lives. For retatrutide, Reko uses a half-life of about 6 days, says on the screen that it is less thoroughly published than for the approved medicines, and shows its status as unapproved.
- An export you can hand to a doctor or study team.
Side effects to log
Write down any symptom, how strong it was and when it began. Side effects seen in trials: In the 2023 obesity trial, side effects were mainly gastrointestinal, dose-related and mostly mild to moderate, and heart rate rose, peaking at 24 weeks (Jastreboff, NEJM 2023). In the 2023 type 2 diabetes trial, gastrointestinal events occurred in 35% of people on retatrutide against 13% on placebo (Rosenstock, Lancet 2023). In the 2026 sleep apnea trials, the most common adverse events were gastrointestinal (Grunstein, NEJM 2026).
For a serious symptom, contact a doctor or emergency services. Tell your study team if you are in a trial. Reko is not a reporting system.
Questions people ask
Can I get retatrutide through Reko?
No. Reko does not sell medicines.
How much should I take?
Reko cannot say. It never suggests a dose. Ask a doctor or your study team.
Does Reko show a plain status for each compound?
Yes. Each of the 50 compounds in Reko has a plain regulatory status.
Is my record private?
Yes. No account is needed and data stays on your iPhone unless you turn on backup.
Related pages
Reko is a record-keeping tool and not medical advice.
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity. N Engl J Med 2023;389:514-526. PubMed. Registry NCT04881760.
- Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, in type 2 diabetes. Lancet 2023;402:529-544. PubMed. Registry NCT04867785.
- Grunstein R et al. Retatrutide once weekly for treatment of obstructive sleep apnea. N Engl J Med, online 21 October 2026. PubMed.
- ClinicalTrials.gov: retatrutide studies. Checked 2 November 2026.
- U.S. Food and Drug Administration warning letter to Amazing Meds, 9 September 2025: "There are no FDA-approved applications on file for your compounded retatrutide drug products." FDA.